Janus Henderson Group PLC Sells 8,326 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Janus Henderson Group PLC lowered its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 1.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 761,772 shares of the company’s stock after selling 8,326 shares during the period. Janus Henderson Group PLC’s holdings in Cryoport were worth $13,483,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of CYRX. Cadian Capital Management LP raised its holdings in Cryoport by 30.4% in the 4th quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock valued at $53,659,000 after acquiring an additional 807,340 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Cryoport by 46.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after buying an additional 636,395 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Cryoport in the 1st quarter valued at approximately $7,800,000. New York State Common Retirement Fund lifted its holdings in shares of Cryoport by 29.9% during the 4th quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock worth $25,446,000 after acquiring an additional 378,340 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Cryoport during the 1st quarter worth approximately $2,905,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Trading Down 5.7 %

Cryoport stock opened at $8.70 on Friday. The firm’s fifty day moving average price is $8.85 and its 200-day moving average price is $13.45. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a quick ratio of 10.22, a current ratio of 10.73 and a debt-to-equity ratio of 0.86.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The firm had revenue of $54.59 million for the quarter, compared to the consensus estimate of $58.78 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. Cryoport’s revenue for the quarter was down 13.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share. As a group, analysts forecast that Cryoport, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on CYRX shares. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Cryoport in a research note on Wednesday, May 8th. B. Riley upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and decreased their price target for the company from $19.00 to $15.00 in a research report on Wednesday. Finally, Jefferies Financial Group began coverage on Cryoport in a report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.86.

Insider Buying and Selling

In other news, insider Edward J. Zecchini sold 3,443 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total transaction of $46,032.91. Following the transaction, the insider now directly owns 60,051 shares of the company’s stock, valued at $802,881.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Edward J. Zecchini sold 3,443 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $13.37, for a total value of $46,032.91. Following the transaction, the insider now owns 60,051 shares in the company, valued at $802,881.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard J. Berman sold 8,105 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at $1,341,000. The disclosure for this sale can be found here. 10.10% of the stock is owned by corporate insiders.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.